SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Pharm Country
Samsung Biologics and TG Therapeutics Expand Collaboration for the Large Scale Manufacture of Ublituximab
April 25, 2021
 · 
7 min read
Drug Development
TG Therapeutics Announces Launch of the ULTRA-V Phase 3 Trial Evaluating the Triple Combination of UKONIQ™ (umbralisib), Ublituximab, and VenetoclaxULTRA-V Phase 2 trial has reached completion of patient enrollment
April 21, 2021
 · 
13 min read
Pharm Country
TG Therapeutics Announces Positive Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at American Academy of Neurology 73rd Annual Meeting
April 16, 2021
 · 
12 min read
Pharm Country
TG Therapeutics to Host Investor & Analyst Event to Preview Results from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple SclerosisWebcast to be held tomorrow, April 16, 2021 at 8:30 AM ET
April 15, 2021
 · 
6 min read
Pharm Country
TG Therapeutics Completes Rolling Submission of Biologics License Application to the U.S. Food and Drug Administration for Ublituximab in Combination with UKONIQ™(umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia
March 29, 2021
 · 
13 min read
BioCapital
Clinical Catch-Up: March 8-12
March 12, 2021
 · 
10 min read
 · 
Mark Terry
Drug Development
TG Therapeutics Announces Publication of Results from the UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed or Refractory Indolent non-Hodgkin Lymphoma in the Journal of Clinical Oncology
March 9, 2021
 · 
12 min read
Pharm Country
TG Therapeutics to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual Meeting
March 4, 2021
 · 
6 min read
Pharm Country
TG Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
March 4, 2021
 · 
1 min read
Business
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2020 Financial ResultsConference call to be held today, Tuesday, March 2, 2021 at 8:30 AM ET
March 2, 2021
 · 
12 min read
Business
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2020 Financial Results and Business UpdateConference call to be held Tuesday, March 2, 2021 at 8:30 AM ET
February 26, 2021
 · 
1 min read
Pharm Country
TG Therapeutics Announces Publication of Final Results from the Phase 3 GENUINE Trial Evaluating Ublituximab Plus Ibrutinib in Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia in The Lancet Haematology
February 23, 2021
 · 
6 min read
FDA
FDA Action Alert: G1, TG and Bristol Myers Squibb and Exelixis
February 12, 2021
 · 
6 min read
 · 
Mark Terry
Policy
Rhizen Pharmaceuticals AG Announces That Its Partnered Asset, Umbralisib (UKONIQ™), Has Received US FDA Accelerated Approval for Adult Patients With Relapsed or Refractory MZL & FL
February 8, 2021
 · 
5 min read
FDA
TG Therapeutics Announces FDA Accelerated Approval of UKONIQ™ (umbralisib)
February 5, 2021
 · 
16 min read
Pharm Country
TG Therapeutics to Participate in the B. Riley Securities Oncology Investor ConferenceFireside chat scheduled for Wednesday, January 20, 2021 at 10:00 AM ET
January 15, 2021
 · 
1 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS